Difference between revisions of "Tepotinib (Tepmetko)"
Jump to navigation
Jump to search
m |
(added package insert) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implicated in many cancers, playing a role in abnormal proliferation, survival, invasion, metastasis, and angiogenesis. | + | Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implicated in many cancers, playing a role in abnormal proliferation, survival, invasion, metastasis, and angiogenesis.<ref name="insert">[https://www.emdserono.com/us-en/pi/tepmetko-pi.pdf Tepotinib (Tepmetko) package insert]</ref><ref>[[:File:Tepotinib.pdf | Tepotinib (Tepmetko) package insert (locally hosted backup)]]</ref><ref>[https://www.tepmetko.com/ Tepmetko manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | ||
| − | |||
| − | |||
| − | |||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Non-small cell lung cancer, MET-mutated]] | *[[Non-small cell lung cancer, MET-mutated]] | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *[https://www.emdserono.com/us-en/pi/tepmetko-pi.pdf Tepotinib (Tepmetko) package insert]<ref name="insert"></ref> | ||
| + | *[http://www.uptodate.com/contents/tepotinib-patient-drug-information Tepotinib (Tepmetko) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/tepotinib-patient-drug-information Tepotinib (Tepmetko) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 22:54, 31 December 2021
General information
Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implicated in many cancers, playing a role in abnormal proliferation, survival, invasion, metastasis, and angiogenesis.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2/3/2021: Granted accelerated approval for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. (Based on VISION)
Also known as
- Code names: EMD-1214063, MSC-2156119, MSC-2156119J
- Brand name: Tepmetko